SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-20-035547
Filing Date
2020-02-13
Accepted
2020-02-13 16:08:09
Documents
7
Period of Report
2020-02-11
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d883470d8k.htm 8-K 23304
2 EX-1.1 d883470dex11.htm EX-1.1 219785
3 EX-5.1 d883470dex51.htm EX-5.1 5466
4 EX-99.1 d883470dex991.htm EX-99.1 9633
5 EX-99.2 d883470dex992.htm EX-99.2 9363
6 GRAPHIC g883470g0213013810820.jpg GRAPHIC 3965
7 GRAPHIC g883470g0213013906778.jpg GRAPHIC 3965
  Complete submission text file 0001193125-20-035547.txt   279978
Mailing Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601
Business Address 180 NORTH LASALLE STREET SUITE 1600 CHICAGO IL 60601 844-445-5704
XERIS PHARMACEUTICALS INC (Filer) CIK: 0001346302 (see all company filings)

IRS No.: 203352427 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38536 | Film No.: 20610506
SIC: 2834 Pharmaceutical Preparations